
|Videos|April 14, 2022
Combining Phenotypic Biomarkers and PET Imaging for Diagnosis and Treatment Selection
Author(s)Scott Tagawa, MD, MS, FACP, FASCO
A focused discussion on how phenotypic biomarkers and positron emission tomography (PET)-based imaging can be combined to diagnose and treat prostate cancer.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5








































